SAN FRANCISCO, Oct. 7, 2020 /PRNewswire/ -- Centaur
Biopharmaceutical Services Inc. (Centaur), a wholly-owned
subsidiary of Kindred Biosciences, Inc. (KindredBio, NASDAQ: KIN),
today announced an expanded agreement between KindredBio and
Vaxart, Inc. (Nasdaq: VXRT) under which Centaur will manufacture
Vaxart's oral vaccine for COVID-19 and other vaccine
candidates.
Centaur is a full-service contract development and manufacturing
organization that specializes in protein-based biologics and
virus-based products. With state-of-the-art facilities in
California and Kansas, Centaur's capabilities span cell line
development, process development, analytical development,
process characterization, clinical manufacturing, and commercial
manufacturing including aseptic fill-and-finish.
"With this major contract, we are pleased to establish Centaur
as a trusted partner for contract manufacturing," said Centaur's
Chief Commercial Officer, Russell
Harris. "We are excited to assist in this important
project."
Under the terms of the expanded agreement, the California plant will be responsible for
scaling the COVID-19 clinical trial material into mid-size
bioreactors and the Kansas plant
will be responsible for manufacturing at 2000L scale in its single
use bioreactors.
About Centaur Biopharmaceutical Services
Centaur Biopharmaceutical Services, Inc. is a full-service
contract development and manufacturing organization that
specializes in protein-based biologics. With state-of-the-art
facilities in California and
Kansas, Centaur's capabilities
span production and process development, analytical
development and process characterization. The team is
experienced in cGMP biologics development, manufacturing, and
aseptic fill-and-finish.
For more information, please visit: www.centaurbps.com/ or
email info@centaurbps.com
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995. All statements contained in this press release that do not
relate to matters of historical fact should be considered
forward-looking statements, including, but not limited to,
statements regarding expectations about the trials, regulatory
approval, manufacturing, distribution and commercialization of
KindredBio's current and future product candidates, and statements
regarding anticipated revenues, expenses, margins, profits and use
of cash.
These forward-looking statements are based on current
expectations. These statements are not promises or guarantees, but
involve known and unknown risks, uncertainties and other important
factors that may cause actual results to be materially different
from any future results expressed or implied by the forward-looking
statements. These risks include, but are not limited to, the
following: KindredBio's limited operating history and expectations
of losses for the foreseeable future; the absence of significant
revenue from KindredBio's products and product candidates for the
foreseeable future; the likelihood that revenue will vary from
quarter to quarter; KindredBio's potential inability to obtain any
necessary additional financing; KindredBio's substantial dependence
on the success of its products and lead product candidates which
may not be successfully commercialized even if they are approved
for marketing; the effect of competition; KindedBio's potential
inability to obtain regulatory approval for existing or future
product candidates; dependence on third parties to conduct some of
KindredBio's development activities; dependence upon third-party
manufacturers for supplies of products and product candidates and
the potential inability of these manufacturers to deliver a
sufficient amount of supplies on a timely basis; the
uncertain effect of the COVID-19 pandemic on KindredBio's business,
results of operations and financial condition; uncertainties
regarding the outcomes of trials regarding product candidates;
KindredBio's potential failure to attract and retain senior
management and key scientific personnel; uncertainty about
KindredBio's ability to enter into satisfactory agreements with
third-party licensees of its biologic products or to develop a
satisfactory sales organization for its equine small molecule
products; KindredBio's significant costs of operating as a public
company; potential cyber-attacks on KindredBio's information
technology systems or on its third-party providers' information
technology systems, which could disrupt operations; KindredBio's
potential inability to repay the secured indebtedness that it has
incurred from third-party lenders, and the restrictions on business
activities that are contained in KindredBio's loan agreement with
these lenders; the risk that KindredBio's 2020 strategic
realignment and restructuring plans will result in unanticipated
costs or revenue shortfalls; uncertainty about the amount of
royalties that KindredBio will receive from the sale of Mirataz® to
Dechra Pharmaceuticals PLC; the potential inability to obtain and
maintain patent protection and other intellectual property
protection for KindredBio's products and product candidates;
potential claims by third parties alleging infringement of their
patents and other intellectual property rights; KindredBio's
potential failure to comply with regulatory requirements, which are
subject to change on an ongoing basis; the potential volatility of
KindredBio's stock price; and the significant control over
KindredBio's business by its principal stockholders and
management.
For a further description of these risks and other risks that
KindredBio faces, please see the risk factors described in
KindredBio's filings with the U.S. Securities and Exchange
Commission (the SEC), including the risk factors discussed under
the caption "Risk Factors" in KindredBio's Annual Report on Form
10-K and any subsequent updates that may be contained in
KindredBio's Quarterly Reports on Form 10-Q filed with the SEC. As
a result of the risks described above and in KindredBio's filings
with the SEC, actual results may differ materially from those
indicated by the forward-looking statements made in this press
release. Forward-looking statements contained in this press release
speak only as of the date of this press release and KindredBio
undertakes no obligation to update or revise these
statements, except as may be required by law.
Contacts
Russell
Harris
russell.harris@centaurbps.com
View original
content:http://www.prnewswire.com/news-releases/centaur-biopharmaceutical-services-announces-expansion-of-manufacturing-agreement-with-vaxart-for-covid-19-and-other-vaccine-candidates-301147331.html
SOURCE Centaur Biopharmaceutical Services Inc.